GlassScriptPhysician profile
David Joseph Chadwick
NPI 1164956041
$10,903.91
in general payments reported to CMS, 2019-2025
52 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $580 · 2021: $2,891 · 2022: $1,570 · 2023: $1,594 · 2024: $2,352 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,861 · Education: $2.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,861.36 |
| Education | $2.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,527.00 | 2020-2025 | Vraylar, Qulipta, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,363.47 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Biohaven Pharmaceuticals, INC. | $1,271.05 | 2021 | |
| Novo Nordisk INC | $1,082.78 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $701.03 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $588.98 | 2020-2025 | Jardiance, Mounjaro, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $488.67 | 2020-2025 | Xifaxan |
| Pfizer INC. | $486.76 | 2020-2025 | |
| Abbott Laboratories | $453.99 | 2021-2025 | Freestyle Libre 3, Octrode, Freestyle Libre 2 |
| Amgen INC. | $389.57 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.23 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $218.85 | 2022-2025 | Veozah, Myrbetriq |
| Alexion Pharmaceuticals, INC. | $217.59 | 2021 | |
| Sumitomo Pharma America, INC. | $213.89 | 2024-2025 | Gemtesa |
| Eisai INC. | $143.88 | 2024-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chadwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.